Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?

Janus kinase inhibitors (JAKis) have revolutionized the treatment landscape for various inflammatory and autoimmune diseases since their introduction in 2012. The expanded indications of JAKis have raised concerns about the associated risk of thrombosis, venous thromboembolic events (VTEs), and arte...

Full description

Saved in:
Bibliographic Details
Main Authors: Yachar Dawudi, Samuel Benarroch, Hélène Helfer, David M. Smadja, Isabelle Mahé
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2475037924003625
Tags: Add Tag
No Tags, Be the first to tag this record!